Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are correct ... I thought it fitting to include in my post because Mr. Allen was spearheading finding something to treat HIV back in the 80s I think.
And fast... they should realize the need to expedite the process even beyond the 'preferencial' treatment they've given CytoDyn... afterall it's a matter of life and death with innocent people dying by the minute around the country and world.
Remdesivir is administered once daily intravenously and takes anywhere from half hour to two hours for ten days... not only is Leronlimab so much more superior in efficacy and safety, but so much easier to administer with just a weekly subcutaneous injection for no more than two weeks to see great results.
https://www.fda.gov/media/137566/download
My pleasure Rockleo; had the same reaction to a great life story... how ironic to be here with Leronlimab (Vyrologix) now. Wish Mr. Allen, founder of CytoDyn could've lived to see this drug hopefully about to go to market for various ailments and especially HIV... maybe save the world from Covid-19!!
Here's some interesting history/reading I was introduced to by lorbas a few days ago:
http://www.allendallen.com/Memorium-Allen-D-Allen.html
I believe Dr. Pourhassan came on board in 2012....
Hope you're having a good weekend, staying safe and very best to all with CYDY!
Actually CytoDyn has 15 employees as of 4/15/2020:
See at bottom of page:
https://www.otcmarkets.com/stock/CYDY/profile
Maybe just not worth responding to crooks such as these and 'boutique' nonsense firms?
And if there needs to be any response, I'd place it within other information... so as not to waste funds on a silly PR... ahaha
Hey rstar good to see you here and exactly stated... tonight's PR is not the first to have :
This was a shorty, very specific... out just a short time ago:
https://www.proactiveinvestors.com/companies/news/919012/cytodyn-shares-manuscript-of-potential-coronavirus-treatment-to-show-validity-of-study-s-findings-919012.html
You sure have... thanks BO!
While "Brilliant" is usually an extraordinary word to describe people, think in the case of folks involved in CytoDyn (especially Pourhassan and Patterson) even their colleagues and professionals in the medical field (life saving) have and will use this deserved terminology ...
Wrote this elsewhere but worth posting here:
While I realize Leronlimab (Vyrologix) was relatively really close to getting to market for HIV, think this tragic CV-19 took over and paved the way to much more... the reputation of these companies has grown and strengthened exponentially (CytoDyn-Dr. Pourhassan, IncellDX-Dr. patterson, Quest Clinical Research-Dr. Lalezari)... I'm naming these particular men but as we all know, it takes teams and lots of folks to brainstorm and do the legwork necessary... my hat's off to all of them!!!
Wonder how long it'll take to evaluate this paper and get it out to the scientific community...
https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1
The names on it are impressive in terms of which entities have been working with Leronlimab (some known to us and some not so much):
IncellDX
Montefiore Medical Center
Amarex Clinical Research
Weill Cornell Medical College
Quest Clinical Research
Oregon Health and Science University
Beckman Coulter
Bio-Rad, Inc.
CytoDyn (of course, aha)
To me, whatever he makes, however he personally uses it... doesn't matter and he deserves it!!!
He's already told me where his heart is....
Side note: Pourhassan is by the book, wants to dot every i and cross every t... and seems from what he's repeatedly stated, has great concern about... even regard for... regulatory processes such as those with the FDA.
I hear him over and over again compliment and appreciate how this one all important regulatory body for Leronlimab is working WITH CytoDyn and even giving the company preferential treatment (on the May 1st CC, Pourhassan answered question regarding competition "Will let Dr. Fauci and Gilead speak about Gilead... they weren't given any special privileges... we were given special privileges).
If you don't believe he and Leronlimab will at this point, I don't know what to say to you....
I've placed my bets on worse .... and came out ahead
Well explained BO!
As I said last night, there are instances where it makes sense to excercise stock options early:
"Once you have a very high degree of confidence your company is going to be a big success and you have some savings you are willing to risk."
Ditto...
Wonder how long it'll take to evaluate this paper and get it out to the scientific community...
https://www.medrxiv.org/content/10.1101/2020....20084673v1
The names on it are impressive in terms of which entities have been working with Leronlimab (some known to us and some not so much):
IncellDX
Montefiore Medical Center
Amarex Clinical Research
Weill Cornell Medical College
Quest Clinical Research
Oregon Health and Science University
Beckman Coulter
Bio-Rad, Inc.
CytoDyn (of course, aha)
Just a side note: saw as of 4/15/20 CytoDyn lists 15 employees...
First post... very nice
By the way, I don't think anyone here or Dr. Pourhassan is telling anyone else what to do with their warrants or begging; just suggesting... it's about saving lives and patients of various illnesses, where timing is of the essence in today's world climate.
There is confidence this is the real drug, real company, real deal for humankind, future growth, success, benefit, financial windfall... if I only had $10-million to give, not just invest, I personally would GIVE it... I realize all have their individual situation(s) but anyone here or elsewhere who is mentioning warrants, is only suggesting. Whatever a shareholder wants to do is up to him/her...
And on another side note, wish I had warrants... would give em up in a heartbeat... don't feel a need for greed!
Very best to you and all with CYDY!
Nice to see someone keeping up with this site... just updated May 1st
https://clinicaltrials.gov/ct2/show/NCT04347239?cond=leronlimab&draw=2&rank=4
Agree... there's a bigger picture out there in our world today.
I'd say he deserves a lot more than that... let's see what he does with it.
It's about saving lives... a man with a heart of gold... an immediate need to get production of a life-saving drug (Leronlimab) to folks in need around the world. Timing is everything as they say... I've written plenty more but will stick with that for now...
I don't get it... why is anyone questioning what Dr. Pourhassan has done...
In today's Proactive interview, he very specifically explained and answered the question saying there were two choices either flood the market with 10M shares and dilute or what he actually did: excercise his own options ... all for the sake of paying for manufacturing of Leronlimab; they had a big payment due.
It wouldn't surprise me if he takes his own profit and invests it right back in the company to get more Leronlimab product manufactured or whatever else is needed.
There are instances where it makes sense to excercise stock options early:
"Once you have a very high degree of confidence your company is going to be a big success and you have some savings you are willing to risk."
Perfect case for CytoDyn!
"Mind blowing" says Dr. Yo of Leronlimab results to be published.... he had said Dr. Bruce Patterson deserves the Nobel prize!
What's also mind blowing is how compassionate, generous and extraordinary CytoDyn's CEO, Dr. Nader Pourhassan is... he has such integrity, heart and unbelievale uniqueness in the OTC world and soon I believe the entire world will see that also.
Dr. Patterson recently said:
Question is: Will Leronlimab (Vyrologix) be among the six?
Remember CytoDyn has, I believe, already had communication with the UK's Health Department....
Good article out yesterday following Monday's shareholder conference call ... it summarized and highlighted several things, especially to newcomers but more could have been dedicated to a most important new discovery Dr. Patterson announced:
COVID-19 IS A RANTES DISEASE = CCL5
Wrote this elsewhere and while the CC was taking place... it's not in mint condition but think as accurate as my typing would produce:
From CC presentation
Dr. Pourhassan: three matters - BLA, Cancer, Covid-19
Four reasons or pushbacks against getting BLA completed with submission... The BLA IS submitted!
Cancer studies: 12 paitents ended up having 0 CTC after treatment... while most could not give blood samples in the last few months because of covid-19... my own family member has seen great results. Her doctor said he never imagined her situation to be like it is today and all the credit for not having brain metastesis, she is doing fantastic... She believes she's alive today because of CytoDyn shareholders... hers is not the only testimony or indication that lives are being saved because of Leronlimab...
Our mission is to save humanity from a powerful plague... had thought BLA filing would be the greatest news but it is not... the fight against covid-19 is:
Blood samples of first 10 patients at Montefiore revealed exciting news... without Dr. Dr. Harish Seethamraju none of these discoveries would have been possible. And Dr. Patterson's tireles work in saving lives... The value one man has brought to us in Dr. Kelly - pushed all the indications of Leronlimab forward.
I went through a lot of challenges in the past eight years and it's thanks to Dr. Kelly still here and it is possible to be here.
CytoDyn has signed agreement with IncellDx (Dr. Patterson) ... out in the next few days and weeks.
As of this morning Dr. Patterson believes he has found several matters that are new to the medical field...
Dr. Patterson:
Pleasure to be able to reveal what we've discovered and how that could potentially help with this horrible pandemic - get people back to work and save patient lives. Covid-19 is a RANTES disease.
Got the following paragraph elsewhere:
RANTES is of broad clinical importance in an array of human diseases including AIDS, cancer, atherosclerosis, asthma, transplantation, and autoimmune diseases such as arthritis, diabetes and glomerulonephritis;6 Box 1 lists a variety of renal diseases in which expression of RANTES is involved.
First to report quantified virus in the plasma... responsible for reduction in plasma in virus... restore immune system and decrease the viral factor in patients. Cautionary... have to be concerned about our blood supply. Dramatic, exciting and unreported findings.
Dr. Lalezari:
Great relief to be able to speak plainly and simply now... not being able to share findings has been agonizing.... My focus with CytoDyn now is three things:
1. Would like to see compassionate use access for ICU and medical professionals - clear this drug is working well
2. Hoping manufacturing is ramped up quickly
3. On 3/20 wrote FDA suggesting compassionate use instead of EIND... based on ICU patients being extubated in 48 hours. Wrote FDA again on 3/27 but they said no.... then key was 4/8 when wrote back to FDA again and now knew Rantes behind the diseases... great luck for CytoDyn and all of humanity being driven by Rantes... last time asked FDA and now coming through EINDs ... no doubt in my mind at all about how important Leronlimab will be.
Pourhassan: Vyrologix
Fundraising... will not raise large funds at .30 because believe will get to a much higher level. Today I am still thinking the same... we are way undervalued. We will update very soon how we're going forward with our fundraising.
Went to question-answer....
On a side note: Thank you Dr. Pourhassan, your team and others who have worked tirelessly to save lives with this horrific pandemic and more (HIV, cancer... and whatever else may come down the pike).
In one hour from now....
Dial-In: 877-407-2986 US / 201-378-4916 International
Thanks Kit
Covid-19 is tragic and devastating to so many around the world in numerous ways but because of it CytoDyn scientists are finding out many new things and ways to help the sick with various ailments... and where other companies/drugs may be failing, Leronlimab is shining... no ordinary drug!
While it was originally designed to tackle HIV and cancer, it's proving to do so much more according to Dr. Patterson and what the medical profession is apparently now seeing.
Loving the terminology in this morning's PR which in light of all said above, is so appropo:
I did not say investor calls are new... nothing new about them... not with CytoDyn or any other OTC... and definitely not new to me (see how many posts I've made and when I got here... and been on numerous OTC calls over the years).
I am relatively new to CytoDyn in that started investing on March 26th but have since bought ten times already... researched it for months prior to that... and am definitely not new to the gutter of the OTC for sure. CytoDyn is exceptional and no ordinary OTC!
I was a news reporter/producer for radio stations... a bit different than this but I'll explain about the PR/RedChip connection below (it may clarify some).
Regarding the CC, I've been on a number of OTC Conference Calls (CCs) and usually they make a presentation (10-15 min.- if CytoDyn has a lot of info, may take longer) and then open the call to investor questions. Some small cap companies ask for shareholder questions in advance and some take them on the fly, if you will, or impromptu at the time of the call. The latter is the one I suspect will take place on Monday with CytoDyn since they have not asked for questions in advance. I feel asking for questions on Monday, hours before the call, is unlikely.
To me, taking questions during the call is better primarily because I or anyone on the call can follow up on something heard said during their presentation... and can ask whatever other questions. Again, I don't see CytoDyn asking for questions to be submitted in advance. And btw analysts are usually prepared.
With regard to these investor PRs, it's more a "Public/Press Release" whereby CytoDyn wants predominantly shareholders, the public, press, analysts to learn of developments. To that end, it has an Investor Relations firm in RedChip to promote the company and what it's doing. The 'source' of the PR is CytoDyn (see bottom of PR - info or content comes from CytoDyn) and I believe RedChip advises, helps write and file the PRs with Globe Newswire which disseminates to a large number of media/press.
Most of the PRs I've seen from CytoDyn have the following at the bottom (I've even seen Dave Gentry interviewing Dr. Pourhassan in a video):
Yes I saw that... it's always best when the reporter/anchor/interviewer is well versed and familiar with the subject (both person and information) he or she is speaking with and articulates well... today's interviewer on CBN (who also did the first one earlier this week) was terrific as she asked the question or made factual comment about the subject, and let her 'guest' say it all (Ms. Mottet was very clear, concise and painted a great picture for the audience). Was also good to hear Dr. Pourhassan on earlier in the week when he was allowed to highlight his important message.
Those type of longer interviews are best as we get to hear it from thee source directly word for word. However if a news story is produced well, that goes a long way on television news especially (TV/cable news time is usually limited).
If a 'guest' understands their time limitation and knows how these interviews work, they can take advantage and clearly present their story and highlight what's important.
Maybe...
While a company can send its press release (PR) to anyone and everyone in the media/press, it's usually up to each outlet to call the company and ask questions... if a company or even an individual decides to hold a 'press conference' they normally send out a PR to the press/media and give specifics for them to send a reporter or attend if they so choose to be there; a reporter may also just call the entity (company/person) to ask them about their 'news.'
Having been in the business, I believe it's still the way it's done....
Regarding an article out yesterday, my understanding is Dr. Jacob Lalezari was interviewed by several journalists/press so I wouldn't be surprised to see more articles and media interviews out... and actually there was another one out today.
Here's a quote from yesterday morning's San Francisco Chronicle (respectable paper):
My understanding is there are millions who watch CBN... will be really great for Leronlimab when the mainstream media is on board, once FDA speaks up.
No I believe Dr. Patterson noted that was a second patient at UCLA
Maybe that second patient him/herself will some day rave about how their life was saved with LERONLIMAB!
Like I wrote elsewere, to hear Samantha Mottet of CA speak of her day-to-day account of what happened to her is nothing short of 'miraculous' and amazing... what a moving testimonial!
https://www1.cbn.com/cbnnews/health/2020/april/california-mom-of-three-survives-after-being-given-experimental-drug-to-fight-covid-19
And now it's on youtube... hope the world gets to hear her story... liver transplant recipient no less:
Read on ....
San Francisco Chronicle
Two drugs studied in Bay Area could lessen coronavirus deaths, hospitalizations
Photo of J.D. Morris
J.D. Morris April 23, 2020 Updated: April 23, 2020 6:25 a.m.
A man wearing a mask walks in Alamo Square Park across from the Painted Ladies, a row of historical Victorian homes in San Francisco. Two treatments being studied in the city could show promise against the coronavirus and COVID-19, the deadly disease it causes.
An image shows monoclonal antibodies at work in the body. These manufactured immune system proteins, which are designed to attack specific targets, are used to treat cancer and other disorders. One is being tested against the coronavirus.
Two drugs being studied by Bay Area doctors for use in fighting coronavirus infections may keep more COVID-19 patients alive and out of the hospital if proved effective.
One of the drugs, colchicine, is a cheap and common anti-inflammatory treatment for gout. UCSF is using it in a clinical trial of COVID-19 patients that is occurring entirely remotely. Patients receive colchicine or placebo pills in the mail and do not need to be seen in person.
The other drug, leronlimab, is a newer experimental treatment that was originally developed for use on HIV patients before being tested more recently on some people with breast cancer. Leronlimab is a monoclonal antibody made by the Vancouver, Wash., company CytoDyn, whose chief science officer is based in San Francisco.
One of the patients who has already been treated with the drug is Samantha Mottet, a 55-year-old resident of Seal Beach (Orange County). She fell ill, primarily with exhaustion, shortly after her husband returned from a trip to the East Coast last month. She was eventually admitted to the hospital at UCLA, where she received an organ transplant 14 years ago, after testing positive for the coronavirus.
Her condition worsened in the hospital and she was placed on a ventilator. The first round of drugs Mottet was given did not improve her COVID-19 symptoms. Then, with her husband’s approval, her doctor administered leronlimab.
Mottet told The Chronicle that the drug was her “last hope” — and it worked. Within 24 hours, she needed less oxygen, and she was taken off the ventilator a few days later. She said she has experienced no side effects.
“All I know is I’m just thankful to be here today,” Mottet said. “This drug worked for me and I hope it works for other people.”
Dr. Warner Greene, a senior investigator with the Gladstone Institutes who has been studying the coronavirus, said leronlimab appears to be “more surgical in its effect.” Colchicine, though well known and widely used, “seems like a blunt instrument for the job at hand,” he said.
Greene said leronlimab is a more targeted kind of drug that would be “interfering with a fundamental part of the process that is causing the trouble.”
“Colchicine may be doing that, but it’s having its effect all over the body,” he said. “That said, if it blocked the cytokine storm ... that would be wonderful.”
Doctors studying leronlimab think it could be broadly effective. While CytoDyn would like to use the drug on ICU patients, its greatest benefit will likely be on patients in earlier stages of COVID-19 — hospitalized people with symptoms more severe than mild shortness of breath, said Lalezari of CytoDyn.
Dr. Bruce Patterson, CEO of the San Carlos single-cell diagnostic company IncellDx that has been working on leronlimab, said the drug is exciting because it appears to impact some of the most essential elements of the viral disease, “not just a piece of what COVID is all about.”
“This is the ideal drug to meet everybody’s needs about reopening the country,” Patterson said. “If we had something that we could say we can treat the severe (patients) and we can keep the mild-to-moderates from getting severe, then it becomes the flu. Then we’re not so scared of people getting infected.”
J.D. Morris is a San Francisco Chronicle staff writer. Email: jd.morris@sfchronicle.com Twitter: @thejdmorris
https://www.sfchronicle.com/health/article/Two-drugs-studied-in-Bay-Area-could-lessen-15219896.php
Who's worried... you're in a real company with real in demand product... one that's actually literally saving lives yet!
Thats' terrific but what's strange is that only two or three hours ago I tried to get more than the two that were listed, and definitely did not see these SIX that now show up... fantastic CytoDyn/leronlimab !!!
Wish they would date when added....
One more apparently just out... diectly from OTC Markets:
https://www.otcmarkets.com/stock/CYDY/news/Next-Super-Stocks-in-News-CYDY-Coronavirus-Treatment-Progress-FBNK-fuboTV-223-million-run-rate-Merger--Streaming-Powerho?id=258032
Thanks for this new video Andy2018... terrific hearing Dr. Pourhassan say they just learned of one of the 10 trial patients being released from hospital today: